Literature DB >> 22487092

Review of the pandemic (H1N1) 2009 among pregnant Japanese women.

Akihito Nakai1, Shigeru Saito, Nobuya Unno, Takahiko Kubo, Hisanori Minakami.   

Abstract

Pregnant women are prone to serious complications when they contract influenza, and a considerable number of pregnant women died from the pandemic (H1N1) 2009 worldwide; however, no maternal mortality occurred in Japan during this pandemic. This review explores the reasons why maternal mortality did not occur in Japan. Two studies conducted during and soon after the pandemic (H1N1) 2009 in Japan suggested the following: 40,000-50,000 pregnant Japanese women took antiviral medicines for prophylaxis after close contact with an infected person; 40% of them (16,000-20,000) contracted the novel influenza and accounted for a half of all 30,000-40,000 pregnant patients with the novel influenza; at least 181 of them required hospitalization; and at least 17 of them developed pneumonitis. Hospitalized women had a 2.5 times higher risk of preterm delivery (at <37 weeks) compared with the general population. The two studies suggested that the following may have contributed to the lack of maternal mortality in Japan: (i) more than 60% of candidates were vaccinated within 1.5 months after the availability of a vaccine against the novel virus; (ii) vaccination reduced the infection rate by 89%; (iii) a large number of women took antiviral drugs before symptom onset after close contact with an infected person; and (iv) approximately 90% of hospitalized pregnant patients took antiviral drugs within 48 hours after symptom onset.
© 2012 The Authors. Journal of Obstetrics and Gynaecology Research © 2012 Japan Society of Obstetrics and Gynecology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22487092     DOI: 10.1111/j.1447-0756.2011.01812.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  10 in total

1.  Influenza 2014-2015 among pregnant Japanese women: primiparous vs multiparous women.

Authors:  T Yamada; S Kawakami; Y Yoshida; H Kawamura; S Ohta; K Abe; H Hamada; S Dohi; K Ichizuka; H Takita; Y Baba; S Matsubara; J Mochizuki; N Unno; Y Maegawa; M Maeda; E Inubashiri; N Akutagawa; T Kubo; T Shirota; Y Oda; T Yamada; E Yamagishi; A Nakai; N Fuchi; H Masuzaki; S Urabe; Y Kudo; M Nomizo; N Sagawa; T Maeda; M Kamitomo; K Kawabata; S Kataoka; A Shiozaki; S Saito; A Sekizawa; H Minakami
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-10       Impact factor: 3.267

Review 2.  Risks associated with viral infections during pregnancy.

Authors:  Karen Racicot; Gil Mor
Journal:  J Clin Invest       Date:  2017-05-01       Impact factor: 14.808

3.  Vaccination during the 2013-2014 influenza season in pregnant Japanese women.

Authors:  T Yamada; K Abe; Y Baba; E Inubashiri; K Kawabata; T Kubo; Y Maegawa; N Fuchi; M Nomizo; M Shimada; A Shiozaki; H Hamada; S Matsubara; N Akutagawa; S Kataoka; M Maeda; H Masuzaki; N Sagawa; A Nakai; S Saito; H Minakami
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-10-14       Impact factor: 3.267

Review 4.  Clinical Effectiveness and Safety of Antivirals for Influenza in Pregnancy.

Authors:  Eric J Chow; Richard H Beigi; Laura E Riley; Timothy M Uyeki
Journal:  Open Forum Infect Dis       Date:  2021-03-20       Impact factor: 3.835

5.  Maternal influenza vaccination relates to receiving relevant information among pregnant women in Japan.

Authors:  Aiko Shono; Shu-Ling Hoshi; Masahide Kondo
Journal:  Hum Vaccin Immunother       Date:  2019-12-18       Impact factor: 3.452

Review 6.  Antivirals in the 2009 pandemic--lessons and implications for future strategies.

Authors:  Deeva Berera; Maria Zambon
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

Review 7.  Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management.

Authors:  Aeron C Hurt; David S Hui; Alan Hay; Frederick G Hayden
Journal:  Influenza Other Respir Viruses       Date:  2014-11-15       Impact factor: 4.380

8.  Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza.

Authors:  Aeron C Hurt; Heath Kelly
Journal:  Emerg Infect Dis       Date:  2016-06       Impact factor: 6.883

9.  The beneficial effects of neuraminidase inhibitor drug therapy on severe patient outcomes during the 2009-2010 influenza A virus subtype H1N1 pandemic.

Authors:  Fred Y Aoki; Frederick G Hayden
Journal:  J Infect Dis       Date:  2012-11-29       Impact factor: 5.226

10.  Second isirv antiviral group conference: overview.

Authors:  Aeron C Hurt; Michael G Ison; Frederick G Hayden; Alan J Hay
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.